VectorBuilder registered an impressive 70% YOY increase in its total orders for 2022, continuing the remarkable growth momentum of the past six years where orders have been rising 70-90% annually.
In addition to the surge in orders, VectorBuilder made notable progress in R&D, production expansion, financing and industry recognition. In early 2022, VectorBuilder began constructing a 100,000 square meter (~1.1 million sq ft) gene delivery R&D and manufacturing facility designed to support an annual revenue of approximately one billion USD. The company has partnered with several gene therapy companies to provide CRO and CDMO services to develop treatment for a range of conditions such as Menkes disease, blood and solid tumors, and spinal cord injury. VectorBuilder’s plasmid and lentiviral vector CDMO products for its US clients have received Investigational New Drug (IND) approval from the FDA. In September, the company completed a C-round financing of 57 million USD. To cap off the year, VectorBuilder won top prize in two influential competitions: the 7th Chuangke Innovation and Entrepreneurship Global Competition and the 11th China Innovation and Entrepreneurship Competition.
“In spite of the challenges from the pandemic, we prevailed because of our unwavering commitment to innovation and quality,” said Dr. Bruce Lahn, Chief Scientist at VectorBuilder. “In the coming years, we will continue to provide the best gene delivery solutions to global life sciences research and genetic medicine R&D.”
